Dr. Maud Reiter is the Director of New & Renewable Ingredients at the corporate R&D Division of Firmenich S.A. in Geneva. Maud received her undergraduate degree from Imperial College, London in 2002, followed by a DPhil under the supervision of Professor Véronique Gouverneur at the University of Oxford. After postdoctoral work with Professor David MacMillan at Caltech/Princeton University, Maud joined Merck& Co. in 2008 in Rahway, NJ, USA as a medicinal chemist. In 2011, Maud then moved to Firmenich, where she is overseeing the discovery of novel & sustainable perfumery ingredients as well as, since September 2020, the implementation of renewable versions of existing ingredients. Firmenich has been innovating in the science of the senses since 1895. Today, with more than 10,000 colleagues in its global family, Firmenich is the largest privately-owned fragrance & taste company in the world, creating fragrances and flavors which touching over 4 billion consumers several times a day, in more than 100+ markets.

Arnaud Bellon is the Senior Vice President – Global Head BU Botanicals & Colors – Cosmetic Ingredients Division, Symrise. After a Post-Master degree focused in Biology & Pharmacology of Ageing from University Pierre et Marie Curie (Paris VI France), he has started his career in Lipo France, a subsidiary of the Lipo Chemicals group (USA), distributor of raw materials for the cosmetics industry. After, he integrated the group Crodarom, manufacturer and distributor of active ingredients and plant extracts for the cosmetic industry. He supervised sales and marketing team for the Asia and North America sectors. He is working in Symrise since 2015 as Senior Vice President and Global Head BU Botanicals & Colors in the Cosmetic Ingredients Division. He implements business strategies consistent with the constraints related to sustainable development

Alexandre Barros is IP and Innovation Manager at 3B's Research Group, University of Minho. He also has his own consultancy company (https://abhealthcare-consulting.com/) working with international companies, start-ups, and Public institutes (Universities, research institutes) with the objective to monetize their intangible assets. A great part of his time he is CEO at HydrUStent SA Company (https://hydrustent.com/) a medical device company that is focused on the development and commercialize innovative medical devices, the business model is to create, validate, patent and sell the technology.

Dan Hallow is a Principal Consultant at Scale-up Systems where he interfaces with scientists and engineers to apply process modelling to increase the efficiency and robustness of pharmaceutical processes development. Dan has spent 14 years in the pharmaceutical industry and has worked across the spectrum of small molecule process development from early pre-clinical deliveries to commercial validation to post-approval support. Dan was formerly a Principal R&D Engineer at Noramco/Purisys, formerly part of Johnson & Johnson, where he was responsible for innovation and technology, including areas such as biocatalysis and crystallization for new and existing products. Before that, Dan was a Senior Research Investigator at Bristol Myers Squibb where his responsibilities included development, scale-up, and tech transfer of pharmaceutical processes for new molecular entities. Dan received the 2015 AIChE PD2M Award for outstanding contribution to QbD for Drug Substance. He holds a PhD in chemical engineering from the Georgia Institute of Technology.

Margarida Gonçalves is Assistant professor at the Department of Science and Technology of the Biomass, Researcher of the Mechanical Engineering and Resource Sustainability Center, Collaborator of the Research Center VALORIZA and coordinator of the MsC in Bioenergy of FCT NOVA. Her research interests include thermochemical conversion techniques for valorization of biomass and waste and characterization of biofuels and biomaterials. She is the author of 13 book chapters and 34 papers in international journals with peer revision, having 54 publications referenced in Scopus.

Dr Quentin Perron is a medicinal chemist. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.